List Price vs. What You Actually Pay
The sticker prices on GLP-1 medications are dramatically high — and almost nobody pays list price. Understanding how to navigate pricing is one of the most practically important things a prospective GLP-1 user can do before starting treatment.
The gap between list price and actual patient cost can be enormous depending on your insurance, employer benefits, and eligibility for manufacturer assistance programs.
| Medication | List Price / mo | With Insurance | Savings Card | Compounded |
|---|---|---|---|---|
| Wegovy (semaglutide) | ~$1,349 | $0–$200 (if covered) | $0–$25 (commercial ins.) | $100–$250 |
| Ozempic (semaglutide, off-label) | ~$935 | $0–$150 (if covered) | $25–$150 | $100–$200 |
| Zepbound (tirzepatide) | ~$1,059 | $0–$200 (if covered) | $25–$550 | $150–$350 |
| Mounjaro (tirzepatide, off-label) | ~$1,069 | $0–$150 (if covered) | $25–$500 | $150–$300 |
| Saxenda (liraglutide) | ~$1,400 | $0–$150 (if covered) | $25–$99 | Not widely available |
Prices above are approximate retail/mail-order prices as of mid-2026. They fluctuate by pharmacy, region, and insurance negotiation. Always get a current quote from your specific pharmacy before making decisions.
Does Insurance Cover GLP-1 Medications?
Insurance coverage is the single largest determinant of what you'll pay. Coverage varies dramatically depending on whether you have commercial insurance, employer-sponsored benefits, Medicare, Medicaid, or no insurance at all.
Commercial (Employer) Insurance
As of 2026, commercial insurance coverage for GLP-1 medications used for weight loss (as opposed to diabetes) is spotty but growing. The key distinction is whether the medication is prescribed for Type 2 diabetes (much more commonly covered) or obesity/weight loss (coverage varies widely).
- Ozempic prescribed for diabetes: Widely covered — most commercial plans include it with standard cost-sharing
- Wegovy/Zepbound for obesity: Coverage varies — many large employers now cover these, many do not; check your specific plan formulary
- Prior authorization: Almost all plans that cover GLP-1s require prior authorization, typically requiring BMI ≥30 (or ≥27 with a weight-related comorbidity) and documentation of prior diet/exercise attempts
- Step therapy: Some plans require you to try and fail cheaper medications first before approving GLP-1s
- Call the member services number on your insurance card
- Ask specifically about Wegovy (NDC 00169-4210-13) and Zepbound (NDC 0002-1590-80)
- Ask what tier they're on, what copay or coinsurance applies, and whether prior auth is required
- Ask whether your plan covers weight management medications at all (some explicitly exclude them)
- Check your plan's drug formulary online — most insurers post searchable formularies
Medicare
Medicare Part D coverage for GLP-1 weight loss drugs improved significantly with the Inflation Reduction Act provisions phasing in through 2025–2026. As of 2026:
- Wegovy for cardiovascular risk reduction: Covered under Medicare Part D for patients with established cardiovascular disease (based on SELECT trial data showing CV event reduction). This is distinct from coverage for obesity alone.
- GLP-1s for diabetes (Ozempic, Mounjaro): Covered under Part D
- Pure weight loss indication (no CV history, no diabetes): Limited coverage — coverage expansion bills have been proposed but federal coverage for pure weight loss is still not universal as of mid-2026
- Medicare Part D cap: $2,000 out-of-pocket cap per year applies to all Part D medications including GLP-1s
Medicaid
Medicaid coverage varies significantly by state. Federal law has historically excluded "weight loss drugs" from Medicaid coverage, but several states have obtained waivers or implemented their own coverage for GLP-1s for obesity. Check your state's Medicaid formulary directly, as this is one of the most rapidly changing areas in GLP-1 access policy.
Manufacturer Savings Programs
Both Novo Nordisk (Wegovy/Ozempic) and Eli Lilly (Zepbound/Mounjaro) offer savings programs for commercially insured patients. These do NOT work for Medicare, Medicaid, or uninsured patients.
Novo Nordisk: NovoCare Savings Card (Wegovy)
- Eligible commercially insured patients can pay as little as $0 for the first month, then $25/month for the first 12 months
- After 12 months, the savings card continues at a higher cap (typically $25–$200/month based on plan)
- Requires commercial insurance — not valid for government-funded plans
- Apply at NovoMedLink or WegovyHCP.com (enroll through your prescribing provider)
Eli Lilly: LillyDirect Savings Card (Zepbound)
- Commercially insured patients can pay as low as $25/month
- For patients without insurance or those whose insurance doesn't cover Zepbound, LillyDirect offers self-pay vials (not pens) at significantly reduced prices: roughly $349–$549/month depending on dose
- LillyDirect self-pay option does not require insurance and ships directly to patients in most states
- Apply at ZepboundSavings.com
LillyDirect's self-pay tirzepatide vials are a meaningful access route for patients without insurance coverage. Vials require drawing and injecting yourself (vs. the auto-injector pens), but the cost difference can be substantial. Many telehealth providers now prescribe and support this format.
Compounding Pharmacies
During the 2022–2025 semaglutide and tirzepatide drug shortages, FDA guidance permitted compounding pharmacies to produce these medications. The shortage status has evolved, and the regulatory landscape for compounded GLP-1s shifted significantly in 2025.
Current Status (Mid-2026)
FDA declared the semaglutide shortage resolved in early 2025, which created legal uncertainty for compounding pharmacies producing semaglutide products. Many telehealth platforms pivoted to:
- Compounded tirzepatide (shortage resolution timeline differed from semaglutide)
- Ozempic/Wegovy via traditional pharmacy with savings cards
- LillyDirect self-pay vials (branded, lower cost)
The legal status of compounded GLP-1 medications has been a rapidly moving target. Before using a compounding pharmacy, verify: (1) the pharmacy is 503B FDA-registered, not just 503A; (2) their GLP-1 products are currently legal to compound under active shortage designations; (3) you're receiving pharmaceutical-grade product, not "peptide research" products from unregulated sources. Unregulated "semaglutide" sold online is a significant patient safety risk.
How Compounding Costs Break Down
Legitimate compounding pharmacies charge roughly $150–$400/month depending on medication and dose. This is typically 50–75% less than brand-name list price. Telehealth platforms that offer compounded GLP-1s often bundle the prescription and pharmacy cost; expect $200–$500/month all-in through these programs.
Telehealth Platforms: What They Offer
A growing ecosystem of telehealth providers specializes in GLP-1 prescriptions. These platforms typically offer:
- Online consultation with a licensed provider (NP or MD), often $0–$200 for the initial visit
- Prescription sent to a partner pharmacy (compounding or traditional)
- Monthly subscription model with ongoing provider access
- Some platforms offer lab work, nutrition coaching, and check-ins bundled in
Telehealth providers vary significantly in quality, regulatory compliance, and what they actually prescribe. Established, reputable platforms work with licensed providers in your state and use 503B-registered pharmacies when compounding is involved.
For a curated list of vetted telehealth GLP-1 providers, see our Find a Provider page.
What to Do If You Can't Afford GLP-1 Medications
If insurance doesn't cover and out-of-pocket costs are prohibitive, here are the options in order of accessibility:
- Apply for manufacturer patient assistance: Novo Nordisk and Lilly both have patient assistance programs (PAPs) for low-income, uninsured patients. Income thresholds apply, but these can provide medications at no cost for eligible patients.
- LillyDirect self-pay vials: Branded tirzepatide at $349–$549/month without insurance — not free, but far below retail pen prices
- Appeal your insurance denial: If you were denied prior authorization, you have the right to appeal. Denials are reversed in a significant percentage of appeals, especially when your provider submits detailed clinical documentation. Ask your prescribing provider about the appeals process.
- Employer benefits advocacy: Some large employers have added GLP-1 coverage in response to employee demand. If your employer doesn't cover them, it's worth raising through HR — enough employee pressure has moved the needle at several large companies.
- State Medicaid waiver programs: If you're on Medicaid, check whether your state has a waiver covering obesity medications. This landscape is evolving quickly.
- GoodRx, Cost Plus Drugs, and pharmacy discount cards: For branded medications, pharmacy discount programs can provide modest savings. They don't change the fundamental cost structure but can help at the margin.
Most people who want access to GLP-1 medications have viable paths to get them at a cost significantly below list price. The key steps: (1) check your specific insurance coverage, (2) apply for manufacturer savings programs if commercially insured, (3) ask your provider about all available options including self-pay vials and compounding before assuming these medications are unaffordable. Don't let the sticker price be the first and last number you see.